|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005684,
umls-concept:C0008838,
umls-concept:C0013216,
umls-concept:C0014582,
umls-concept:C0025677,
umls-concept:C0032246,
umls-concept:C0042670,
umls-concept:C0205281,
umls-concept:C0600558,
umls-concept:C0683956,
umls-concept:C0812425,
umls-concept:C0871261,
umls-concept:C1274040,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2002-5-10
|
|
pubmed:abstractText |
To investigate the value of DNA ploidy and S-phase fraction (SPF) as factors that could predict response and outcome of invasive transitional cell carcinoma (TCC) of the bladder to neoadjuvant methotrexate, vinblastine, epirubicin and cisplatin (MVEC) chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0036-5599
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
46-51
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12002357-Aged,
pubmed-meshheading:12002357-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12002357-Carcinoma, Transitional Cell,
pubmed-meshheading:12002357-Cisplatin,
pubmed-meshheading:12002357-DNA, Neoplasm,
pubmed-meshheading:12002357-Disease-Free Survival,
pubmed-meshheading:12002357-Epirubicin,
pubmed-meshheading:12002357-Female,
pubmed-meshheading:12002357-Flow Cytometry,
pubmed-meshheading:12002357-Humans,
pubmed-meshheading:12002357-Male,
pubmed-meshheading:12002357-Methotrexate,
pubmed-meshheading:12002357-Middle Aged,
pubmed-meshheading:12002357-Neoadjuvant Therapy,
pubmed-meshheading:12002357-Ploidies,
pubmed-meshheading:12002357-S Phase,
pubmed-meshheading:12002357-Survival Rate,
pubmed-meshheading:12002357-Urinary Bladder Neoplasms,
pubmed-meshheading:12002357-Vinblastine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
DNA ploidy and S-phase fraction as predictive factors of response and outcome following neoadjuvant methotrexate, vinblastine, epirubicin and cisplatin (M-VEC) chemotherapy for invasive bladder cancer.
|
|
pubmed:affiliation |
Department of Urology, University of Ankara, School of Medicine, Turkey.
|
|
pubmed:publicationType |
Journal Article
|
